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doi:10.1016/j.pedneo.2010.12.010Although the safety profile of tetanus toxoid, reduced diphtheria toxoid, and acellular
pertussis (Tdap) vaccines in adolescents and adults has been documented, few data have
reported about their adverse events in children. Healthy 6- to 7-year-old children who were
immunized with Tdap vaccine were evaluated for adverse events on Days 1, 2, 4, and 7 post-
immunization. Information of sex, body mass index (BMI), and previous diphtheria-pertussis-
tetanus (DPT) immunization history was obtained and evaluated for the association with the
adverse events. A total of 243 6- to 7-year-old children were immunized with Tdap. Among
the 243 children immunized, remarkable adverse events included redness more than or equal
to 10 mm in 47 (19%) children, induration more than or equal to 10 mm in 57 (23%), tenderness
in 130 (53%), and fever in 12 (5%). Redness and induration resolved in 7 days and fever resolved
on Day 4. The adverse events were not associated with gender, BMI above the mean value, or
the type of fourth DPT immunization. Adverse events after Tdap vaccination were mild and dis-
solved within 7 days in 6- to 7-year-old children.
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Adverse effects of Tdap vaccine 391. Introduction
A tetanus toxoid, reduced diphtheria toxoid, and acellular
pertussis (Tdap) vaccine product, Adacel (Sanofi-Pasteur,
Swiftwater, PA, USA), was licensed as a booster vaccine
against diphtheria, tetanus, and pertussis for adolescents
and adults in the United States in 2005. Although the safety
and efficacy of the Tdap vaccine in adolescents and adults
have been documented, few reports describing the adverse
events in children have been published.1e3
According to the data of the Notifiable Disease Surveil-
lance System of Taiwan, the number of patients with labo-
ratory-confirmed pertussis increased from 6 in 2001 to 41 in
2008.4 During the same period, the number of suspected
pertussis cases was between 154 and 190 annually. A total of
239 suspected pertussis cases and 89 microbiologically
confirmed infections were recorded in Taiwan in 2009
(unpublished data). In view of the increased pertussis burden
in Taiwan, the Taiwan Advisory Committee on Immunization
Practices recommended Tdap vaccine, rather than teta-
nusediphtheria (Td) vaccine, to be administered in grade 1
children in primary school starting in 2009. With the imple-
mentation of Tdap immunization in early 2009, reports of
adverse reactions such as large redness or induration after
vaccination drew the attention of the public health author-
ities (Figure 1). We thus conducted a prospective observa-
tional study to assess the adverse events following Tdap
vaccination in 6- to 7-year-old children.
2. Method
The study was conducted at a primary school. All healthy 6-
to 7-year-old children of the first grade who had no
contraindication to receive immunization were eligible for
immunization. Children were excluded if they received
medications (including antihistamines) regularly, had
received any blood product within 3 months, or had infec-
tious ailments including upper respiratory tract infection or
infectious gastroenteritis. Minor health conditions such as
eczema, asthma, and minor abrasions did not excludeFigure 1 An induration and redness with a diameter of
6.7 cm was found at the left arm of a 7-year-old child who had
received Tdap immunization 2 days before.participation in the study. All the children were examined
for enrollment by a physician before immunization.
Thedemographicdata, including gender andage, andbody
mass index (BMI) measured within 3 months of vaccination,
were provided by the school health center. The immunization
records of the previous 4 doses of either DTwP or DTaP were
obtained from the National Immunization Information System
(NIIS), a digital immunization registry system, which physi-
cians have to record all vaccines administered in children. For
the previous immunization, DTwP vaccine had been provided
by the government and was a product of Sanofi Pasteur, Tor-
onto, Ontario, Canada. However, DTaP was provided by
multiplemanufacturers in theprivatemarket, and the specific
brand of DTaP was not available in NIIS.
All the enrolled subjects received a booster dose of Tdap
vaccine (Adacel, Sanofi Pasteur, Toronto, Ontario,
Canada) on Day 0. Each dose of the Tdap vaccine contained
2 limit of flocculation (Lf) diphtheria toxoid, 5 Lf tetanus
toxoid, 2.5 mg detoxified pertussis toxin, 5 mg filamentous
haemagglutinin, 3 mg pertactin, 5 mg each of fimbriae types
2 and 3, 0.33 mg aluminum hydroxide, and 3.3 mg 2-phe-
noxyethanol. The vaccine was of the same lot and admin-
istered intramuscularly into the deltoid muscle of the non-
dominant arm, using a 1-inch-long 25-gauge needle by
a single nurse who had been trained for Tdap immunization.
Enrolled children were assessed by the same study
physician on Day 1 (24 hours later), Day 2 (48 hours later),
Day 4 (96 hours later), and Day 7 (168 hours later). Solicited
adverse events included injection site redness, induration,
tenderness, itching, fever, headache, and gastrointestinal
symptoms. Unsolicited symptoms were recorded according
to the children’s description.
c2 analysis and multivariable logistic regression models
were used to identify risk factors for local and systemic
adverse events including redness, induration, fever, and
tenderness. Potential risk factors included sex, BMI above
the mean value of the enrolled children, and the type of
the fourth DTwP/DTaP vaccination. Statistical analyses
were performed using Stata software, version 10 (Stata
Corp LP, College Station, Texas, USA). A p < 0.05 was
considered to be statistically significant.3. Results
A total of 263 children were evaluated. Among these chil-
dren, 20 were excluded. The mean age of the 243 children
enrolled was 7.2 years (range, 6.7e7.8 years). Forty-four
percent were male. The mean height was 121.2 cm (range,
105.0e139.2 cm). The average BMI was 16.8 (range,
12.6e30.8).
Of the 243 enrolled subjects, 242 (99.6%) received 4
doses of DTwP/DTaP vaccine as the priming immunization,
and 1 received the first 3 doses and missed the fourth dose
of DTwP/DTaP. All the 243 children received government-
provided DPwT vaccine for the first 3 doses. For the fourth
dose, 222 (91.7%) received DPwT and 20 (8.3%) received
DTaP vaccine.
After vaccination with Tdap, 170 (70%) reported at least
1 adverse event (Table 1). Five (2%) had Tdap immuniza-
tion-related adverse events (i.e., fever and local tender-
ness) severe enough to result in missed school for at least
Table 1 Signs and symptoms among 243 grade one students who received Tdap immunization, observed on Days 1e7
postimmunization
Observed Day 1 (%) Day 2 (%) Day 4 (%) Day 7 Total (%)
Redness (mm)
10 5 (2) 44 (18) 5 (2) 0 47 (19)
25 4 (2) 41 (17) 5 (2) 0 44 (18)
50 2 (1) 7 (3) 2 (1) 0 10 (4)
Induration (mm)
10 22 (9) 47 (19) 5 (2) 0 57 (23)
25 20 (8) 40 (16) 2 (1) 0 49 (20)
50 2 (1) 7 (3) 1 0 10 (4)
Tenderness 72 (30) 77 (32) 46 (19) 13 (5) 130 (53)
Itching 7 (3) 6 (2) 4 (2) 9 (4) 21 (9)
Fever
37.5C 11 (5) 1 0 0 12 (5)
39C 1 0 0 0 1
Headache 12 (5) 11 (5) 8 (3) 9 (4) 31 (13)
Vomiting 5 (2) 1 1 1 8 (3)
One child had a swollen arm and numbness of all the digits on Day 2 and his symptom had subsided by Day 4.
One child had general skin rash on Day 1 through Day 4.
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peaked on Day 2. The most severe redness occurred in a girl
4 days after vaccination, measuring 85 mm in diameter. The
most prominent induration occurred in a boy 2 days after
vaccination, measuring 66 mm in diameter. One overweight
boy with a BMI of 23.1 reported numbness of the digits of
the vaccinated arm on Day 2, and his numbness resolved by
Day 4. General macular rash was found in a boy from Day 1
through Day 4. Twenty-one (9%) children reported itching
around the injection site, with or without local redness and
induration. No children were found febrile after Day 4. All
the redness and induration resolved on Day 7. None of the
children in our study experienced seizure, major neurologic
reaction or other uncommon events.
Sex, BMI above the mean value of the same age group,
and the type of the fourth DTwP/DTaP vaccination were not
associated with redness (10 mm, 25 mm, 50 mm),
induration (10 mm, 25 mm, 50 mm), tenderness or
fever (37.5C) in both univariate andmultivariate analysis.4. Discussion
Reactogenicity of DTaP has been shown to be increased
with successive doses in older children.5 There are prece-
dent studies reporting the immunogenicity and reac-
togenicity of vaccines with reduced antigens as a fifth dose
for children.1,6,7 Scheifele et al1 had reported that Tdap
vaccination in 4- to 6-year-old children primed with 4 doses
of DTaP caused significantly fewer local reactions than
DTaP did. Our study featured the reactogenic profile of
Tdap vaccine in children primed with mainly doses of DTwP.
It has been reported that children with a BMI above the
median value were more likely to have local redness
because Tdap vaccine is less reliably injected into muscle
tissue of these children.8 In the present study, no similar
trend was observed. We sought to minimize the probability
of inadequate depth vaccine delivery by using 1-inch-longneedles and reminding the vaccine-delivery personnel to
deliver the vaccines appropriately.
Given that gender preponderance in response to Tdap
antigens remained unclear, we did not find significant
association between gender and local or systemic reac-
tions. In a study on adverse events of Tdap in adult health
care workers, women were three times more likely to
experience local adverse events after Tdap administration
than men.9 In another study, Scheifele et al reported that
a significantly greater proportion of children with large
reactions to DTaP-IPV were male.
Safety and immunogenicity of mixed scheduled immu-
nization of DTwP, DTaP, and Tdap have been an issue of
concern. It has been reported that adverse events following
the fifth dose of DTaP vaccine were similar whether given as
a fifth sequential dose of the same vaccine, a mix of
different brands of DTaP vaccines in the 5-dose sequence,
or after 3 DTwP and 1 DTaP vaccinations.10 In this study, we
found that the local and systemic adverse events following
the fifth dose of Tdap vaccination were generally similar in
children who had previously received 4 DTwP immuniza-
tions or 3 DTwP and fourth DTaP immunization. Our data,
together with previous studies, suggested the encouraging
safety profile in mixed scheduled vaccination.
Currently, there are two Tdap vaccines licensed for
vaccination in adolescents and adults in the United States:
Boostrix (GlaxoSmithKline’s, Rixensart, Belgium) and Ada-
cel. Although both comprise reduced antigens of diph-
theria, tetanus, and pertussis, they are different from each
other in quantity and type of antigens. Blatter et al have
shown that overall safety profile of Boostrix was generally
comparable to that of Adacel in adults aged 19e64 years.3
Comparing with Blatter’s report, we found local reactions
and fever elicited by Adacel in children were comparable to
those in adults. However, the rate of headache in children
seemed less than that in adults (13% vs. 31%).3 Huang et al7
had assessed the immunogenicity and reactogenicity of
Boostrix in 6- to 8-year-old children primed with 4 doses of
Adverse effects of Tdap vaccine 41DTwP/DTaP. We found higher rates of severe local reactions
and fever in children who received Adacel than those who
received Boostrix (redness 50 mm, 4% vs. 0%; induration
50 mm, 4% vs. 0%; fever 37.5C, 5% vs. 0%). Whether it
suggested that Boostrix causes milder symptoms than
Adacel in children deserves further investigation. However,
the comparison is not exempted from potential observa-
tional bias with different observers and settings.
Our study has several limitations. We only monitor the
adverse events for 7 days and may have missed late-
occurring events. Although we observed the adverse events
by a single study physician to minimize the observer-asso-
ciated difference, some parameters, e.g., diameter of
induration, might be difficult to be measured consistently.
In the absence of a control group, it is possible that the
adverse events observed did not represent an adverse
reaction. However, we found no evidence to support this
possibility.
Although some children/subjects experienced adverse
events after Tdap immunization, the adverse events were
mild and resolved within 7 days. Sex, BMI above the mean
value, and the fourth dose of DTwP/DTaP were not asso-
ciated with the occurrence of adverse events.
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